AlphaStocks
6.2
Consider Buy

Indivior Pharmaceuticals, Inc. (INDV)

Health Care / Pharmaceuticals

S&P SmallCap 600

$30.66

Middle of the pack. No strong signal either way.

Consider Buy

Score based on 4 of 5 models — moderate confidence

#248out of 1127 in Health Care

Is Indivior Pharmaceuticals, Inc. a Good Investment in 2026?

Indivior Pharmaceuticals, Inc. (INDV) scores 6.2 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Greenblatt Magic Formula model rates Indivior Pharmaceuticals, Inc. as Attractive (Top 10% (rank 1%)). However, the Graham model rates it Caution. Indivior Pharmaceuticals, Inc. currently trades below its estimated fair value of $44, suggesting potential upside. Indivior Pharmaceuticals, Inc. ranks #248 out of 1127 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E18.7ROE-60.3Market Cap4B

Estimated Fair Value

$44.1531% below

Fair value above market price. EPS grew 3017% year-over-year. P/E of 19x is moderate for this quality level.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Neutral

4/9

Buffett

Neutral

Business quality & competitive moat

Graham

Caution

Price vs intrinsic value

Lynch

Limited Data

Growth rate vs price (PEG)

Greenblatt

Attractive

Top 10% (rank 1%)

Frequently Asked Questions

Is Indivior Pharmaceuticals, Inc. (INDV) a good investment?
Based on AlphaStocks' composite analysis, Indivior Pharmaceuticals, Inc. (INDV) scores 6.2 out of 10, earning a Consider Buy rating. This is a middle-of-the-pack score with no strong signal either way. Fair value above market price. EPS grew 3017% year-over-year. P/E of 19x is moderate for this quality level.
What is Indivior Pharmaceuticals, Inc.'s Piotroski F-Score?
Indivior Pharmaceuticals, Inc.'s Piotroski F-Score status is Neutral. The raw score is 4/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is INDV overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $44, INDV appears undervalued. The stock currently trades 31% below its estimated fair value. Fair value above market price. EPS grew 3017% year-over-year. P/E of 19x is moderate for this quality level.
How does INDV compare to other Health Care stocks?
Indivior Pharmaceuticals, Inc. ranks #248 out of 1127 stocks in the Health Care sector, placing it in the top 22% of its sector by composite score. This is a strong position relative to sector peers.
What do investment models say about INDV?
AlphaStocks evaluates INDV using five proven investment models. Piotroski: Neutral; Buffett: Neutral; Graham: Caution; Greenblatt Magic Formula: Attractive. These models are combined into a single composite score of 6.2/10.

Similar Stocks

PARRFTIAZN

Compare INDV with

INDV vs PARRINDV vs FTIINDV vs AZN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer